A., Miecz, D., Berezowski, V., & Cecchelli, R
Note that while there are compounded versions of tirzepatide and semaglutide, these drugs are not FDA approved
Mechanisms of action of Semaglutide is a GLP-1 receptor agonist that works by stimulating insulin secretion and reducing glucagon production
[1] Unlike SGLT2 inhibitors used for diabetes management, which work by increasing glucose excretion through urine and consequently cause increased urination, Zepbound operates through an entirely different mechanism
For direct vasomotor symptom relief, hormone therapy or other interventions remain the primary treatment
The implication is important: there's an asymmetry to the trade-off